licensing

News

Dr Dean Li, president of Merck Research Laboratories

MSD licenses Lp(a) heart drug from Hengrui in $2bn deal

MSD has fleshed out its cardiovascular disease pipeline by licensing an oral Lp(a) inhibitor from China's Jiangsu Hengrui Pharma for $200m upfront.

News

Novo Nordisk looks east for another obesity therapy

Novo Nordisk has moved to shore up its obesity pipeline with a $2bn licensing deal for a triple agonist developed by China's United Biotechnology.

News

AstraZeneca buys cell therapy biotech for up to $1bn

AstraZeneca plans to acquire Belgian in vivo cell therapy biotech EsoBiotec and has signed a pair of licensing deals with drug delivery firm Alteogen.

News

Roche builds in obesity with $5.3bn Zealand licensing deal

Roche has parted with $1.4 billion upfront to secure rights to an obesity candidate developed by Zealand Pharma.

News

AbbVie pays Gubra $350m upfront to enter obesity field

AbbVie has joined the ranks of pharma groups trying to develop weight-loss drugs, licensing an amylin agonist from Gubra in a $2.2bn-plus deal.

News

Biogen bags rights to epilepsy drug from Stoke in $550m deal

Biogen has bolstered its pipeline by licensing ex-US rights to a drug for Dravet syndrome – a rare form of epilepsy – from Stoke Therapeutics.

MSD licenses Lp(a) heart drug from Hengrui in $2bn deal

Novo Nordisk looks east for another obesity therapy

AstraZeneca buys cell therapy biotech for up to $1bn

Roche builds in obesity with $5.3bn Zealand licensing deal

AbbVie pays Gubra $350m upfront to enter obesity field

Biogen bags rights to epilepsy drug from Stoke in $550m deal

Lily gets FDA nod for SERD-CDK 4/6 combo in breast cancer

Discover a new era of healthcare panel engagement: Grounded ...

licensing

Editor's Picks